A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage
- 1.2k Downloads
Accurate early anticipation of long-term irreversible brain damage during the acute phase of patients with aneurysmal subarachnoid hemorrhage (aSAH) remains difficult. Using a combination of clinical scores together with brain injury-related biomarkers (H-FABP, NDKA, UFD1 and S100β), this study aimed at developing a multiparameter prognostic panel to facilitate early outcome prediction following aSAH.
Blood samples of 141 aSAH patients from two separated cohorts (sets of 28 and 113 patients) were prospectively enrolled and analyzed with 14 months of delay. Patients were admitted within 48 h following aSAH onset. A venous blood sample was withdrawn within 12 h after admission. H-FABP, NDKA, UFD1, S100β and troponin I levels were determined using classical immunoassays. The World Federation of Neurological Surgeons (WFNS) at admission and the Glasgow Outcome Score (GOS) at 6 months were evaluated.
In the two cohorts, blood concentration of H-FABP, S100β and troponin I at admission significantly predicted unfavorable outcome (GOS 1–2–3). A multivariate analysis identified a six-parameter panel, including WFNS, H-FABP, S100β, troponin I, NDKA and UFD-1; when at least three of these parameters were simultaneously above cutoff values, prediction of unfavorable outcome reached around 70% sensitivity in both cohorts for 100% specificity.
The use of this panel, including four brain injury-related proteins, one cardiac marker and a clinical score, could be a valuable tool to identify aSAH patients at risk of poor outcome.
KeywordsAneurysmal subarachnoid hemorrhage H-FABP NDKA S100β Prognosis
Heart-fatty acid binding protein
Nucleoside diphosphate kinase A
Ubiquitin fusion degradation protein-1
Aneurysmal subarachnoid hemorrhage
The authors thank the chief nurses and nurses of the Pitié-Salpêtrière Hospital for their remarkable work in the collection of samples. The collection of samples was funded by the Direction for Clinical Research of the Assistance Publique-Hôpitaux de Paris. This work was also kindly supported by Proteome Sciences plc.
Conflicts of interest statement
Neither financial interest nor conflicts of interest are related to this publication.
- 13.Turck N, Vutskits L, Sanchez-Pena P, Robin X, Hainard A, Gex-Fabry M, Fouda C, Mueller M, Puybasset L, Sanchez JC (2009) A multiparameter panel method for outcome prediction following aneurysmal subarachoid hemorrhage. In: 5th International conference on biochemical markers for brain damage, 11–14 May, Lund, SwedenGoogle Scholar
- 14.Turck N, Vutskits L, Sanchez-Pena P, Robin X, Hainard A, Gex-Fabry M, Fouda C, Mueller M, Puybasset L, Sanchez JC (2008) From the proteomics to the clinical study: identification of a multiparameter panel for outcome prediction following aneurysmal subarachnoid hemorrhage. In: 8th Siena meeting from genome to proteome: integration and plateform completion: August 31st–September 4th, Siena, ItalyGoogle Scholar
- 15.Turck N, Vutskits L, Sanchez-Pena P, Robin X, Hainard A, Gex-Fabry M, Fouda C, Mueller M, Puybasset L, Sanchez JC (2008) A multiparameter panel method for outcome prediction following aneurysmal subarachoid hemorrhage. In: XVII European stroke conference, 13–16 May, Nice, FranceGoogle Scholar
- 16.Drake C (1988) Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 68:985–986Google Scholar
- 38.Tanaka T, Sohmiya K, Kitaura Y, Takeshita H, Morita H, Ohkaru Y, Asayama K, Kimura H (2006) Clinical evaluation of point-of-care-testing of heart-type fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. J Immunoassay Immunochem 27:225–238CrossRefPubMedGoogle Scholar